Ahmad Kunbaz, A. Warrington, M. Perwein, Mahboobeh Fereidan-Esfahani, Moses Rodriguez
{"title":"A natural human monoclonal antibody protects from axonal injury in different CNS degenerative disease models","authors":"Ahmad Kunbaz, A. Warrington, M. Perwein, Mahboobeh Fereidan-Esfahani, Moses Rodriguez","doi":"10.2217/FNL-2017-0027","DOIUrl":"https://doi.org/10.2217/FNL-2017-0027","url":null,"abstract":"","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"13 1","pages":"23-29"},"PeriodicalIF":1.3,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/FNL-2017-0027","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41912840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-02-01Epub Date: 2018-01-17DOI: 10.2217/fnl-2017-0028
Emily A André, Patrick A Forcelli, Daniel Ts Pak
Brain activity levels are tightly regulated to minimize imbalances in activity state. Deviations from the normal range of activity are deleterious and often associated with neurological disorders. To maintain optimal levels of activity, regulatory mechanisms termed homeostatic synaptic plasticity establish desired 'set points' for neural activity, monitor the network for deviations from the set point and initiate compensatory responses to return activity to the appropriate level that permits physiological function [1,2]. We speculate that impaired homeostatic control may contribute to the etiology of various neurological disorders including epilepsy and Alzheimer's disease, two disorders that exhibit hyperexcitability as a key feature during pathogenesis. Here, we will focus on recent progress in developing homeostatic regulation of neural activity as a therapeutic tool.
{"title":"What goes up must come down: homeostatic synaptic plasticity strategies in neurological disease.","authors":"Emily A André, Patrick A Forcelli, Daniel Ts Pak","doi":"10.2217/fnl-2017-0028","DOIUrl":"https://doi.org/10.2217/fnl-2017-0028","url":null,"abstract":"<p><p>Brain activity levels are tightly regulated to minimize imbalances in activity state. Deviations from the normal range of activity are deleterious and often associated with neurological disorders. To maintain optimal levels of activity, regulatory mechanisms termed homeostatic synaptic plasticity establish desired 'set points' for neural activity, monitor the network for deviations from the set point and initiate compensatory responses to return activity to the appropriate level that permits physiological function [1,2]. We speculate that impaired homeostatic control may contribute to the etiology of various neurological disorders including epilepsy and Alzheimer's disease, two disorders that exhibit hyperexcitability as a key feature during pathogenesis. Here, we will focus on recent progress in developing homeostatic regulation of neural activity as a therapeutic tool.</p>","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"13 1","pages":"13-21"},"PeriodicalIF":1.3,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/fnl-2017-0028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35776204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elyar Sadeghi-Hokmabadi, M. Farhoudi, A. Taheraghdam, R. Rikhtegar, R. Ghafouri, Rogayyeh Asadi, Elham Mehdizadeh Far, N. Ghaemian, Mehrdad Mehrara, Reshad Mirnour
Pub Date : 2018-02-01Epub Date: 2018-01-17DOI: 10.2217/fnl-2017-0030
Brian A Zaboski, Eric A Storch
Appearing in 40% of the cases of autism spectrum disorder (ASD), comorbid anxiety presents unique challenges for practitioners by amplifying problem behaviors such as social skills deficits, resistance to change and repetitive behaviors. Furthermore, comorbid ASD/anxiety strains familial relationships and increases parental stress. Research indicates that the neurobiological interactions between anxiety and ASD require comprehensive assessment approaches, modified cognitive behavioral therapy and carefully managed pharmacological interventions. Meta-analyses indicate that cognitive behavioral therapy with exposure is an effective treatment option when adequately accounting for social, familial and cognitive variables. The purpose of this focused review is to update readers on the latest research advances in comorbid ASD and anxiety, including prevalence, assessment, psychosocial and pharmacological treatment.
{"title":"Comorbid autism spectrum disorder and anxiety disorders: a brief review.","authors":"Brian A Zaboski, Eric A Storch","doi":"10.2217/fnl-2017-0030","DOIUrl":"10.2217/fnl-2017-0030","url":null,"abstract":"<p><p>Appearing in 40% of the cases of autism spectrum disorder (ASD), comorbid anxiety presents unique challenges for practitioners by amplifying problem behaviors such as social skills deficits, resistance to change and repetitive behaviors. Furthermore, comorbid ASD/anxiety strains familial relationships and increases parental stress. Research indicates that the neurobiological interactions between anxiety and ASD require comprehensive assessment approaches, modified cognitive behavioral therapy and carefully managed pharmacological interventions. Meta-analyses indicate that cognitive behavioral therapy with exposure is an effective treatment option when adequately accounting for social, familial and cognitive variables. The purpose of this focused review is to update readers on the latest research advances in comorbid ASD and anxiety, including prevalence, assessment, psychosocial and pharmacological treatment.</p>","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"13 1","pages":"31-37"},"PeriodicalIF":1.3,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772195/pdf/fnl-13-31.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35776205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Traumatic brain injuries in victims of intimate partner violence: an underappreciated source of neurological morbidity","authors":"K. Monahan, Andrew M. Goldfine, A. Biegon","doi":"10.2217/FNL-2017-0026","DOIUrl":"https://doi.org/10.2217/FNL-2017-0026","url":null,"abstract":"","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"12 1","pages":"189-191"},"PeriodicalIF":1.3,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/FNL-2017-0026","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46515038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Celebrating 50 years of neuroscience research at Lilly's Erl Wood site","authors":"Adam Price-Evans","doi":"10.2217/FNL-2017-0023","DOIUrl":"https://doi.org/10.2217/FNL-2017-0023","url":null,"abstract":"","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"12 1","pages":"193-198"},"PeriodicalIF":1.3,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/FNL-2017-0023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46298559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Bozzatello, Camilla Ghirardini, Maria Uscinska, P. Rocca, S. Bellino
Pharmacotherapy for personality disorders is in the early stage of development because the evidence base for effective drug treatment is insufficient, biased toward borderline personality disorder and rampant with methodological issues. In this paper, we reviewed randomized, placebo-controlled trials of drugs efficacy in patients with personality disorders published between 1990 and 2016. Overwhelming majority of studies focused on borderline personality disorder (BPD), and the accumulation of evidence resulted in 7 meta-analyses, which are interpreted into better strategies for evidence-based practice. Little research attention was given to schizotypal (SPTD) and antisocial (ASPD) personality disorders, with only indirect treatment efficacy evidence for the obsessive-compulsive (OCPD) and avoidant (AvPD) personality disorders. Some avenues for future efficacy research are indicated. respectively on a fair (level B) and minimal (level C) research-based evidence level. The main symptomatic targets of pharmacotherapy in personality disorders, according to WFSBP guidelines, are affective dysregulation, cognitive-perceptual symptoms, impulsivity and anger. The effects of pharmacotherapy in these patients can also be useful to increase response to combined psychosocial interventions.
{"title":"Pharmacotherapy of personality disorders: what we know and what we have to search for","authors":"P. Bozzatello, Camilla Ghirardini, Maria Uscinska, P. Rocca, S. Bellino","doi":"10.2217/FNL-2017-0010","DOIUrl":"https://doi.org/10.2217/FNL-2017-0010","url":null,"abstract":"Pharmacotherapy for personality disorders is in the early stage of development because the evidence base for effective drug treatment is insufficient, biased toward borderline personality disorder and rampant with methodological issues. In this paper, we reviewed randomized, placebo-controlled trials of drugs efficacy in patients with personality disorders published between 1990 and 2016. Overwhelming majority of studies focused on borderline personality disorder (BPD), and the accumulation of evidence resulted in 7 meta-analyses, which are interpreted into better strategies for evidence-based practice. Little research attention was given to schizotypal (SPTD) and antisocial (ASPD) personality disorders, with only indirect treatment efficacy evidence for the obsessive-compulsive (OCPD) and avoidant (AvPD) personality disorders. Some avenues for future efficacy research are indicated. respectively on a fair (level B) and minimal (level C) research-based evidence level. The main symptomatic targets of pharmacotherapy in personality disorders, according to WFSBP guidelines, are affective dysregulation, cognitive-perceptual symptoms, impulsivity and anger. The effects of pharmacotherapy in these patients can also be useful to increase response to combined psychosocial interventions.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"12 1","pages":"199-222"},"PeriodicalIF":1.3,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/FNL-2017-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45498492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Genetics of Alzheimer's disease: an update","authors":"M. Tang, C. Reitz","doi":"10.2217/FNL-2017-0003","DOIUrl":"https://doi.org/10.2217/FNL-2017-0003","url":null,"abstract":"","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"12 1","pages":"237-247"},"PeriodicalIF":1.3,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/FNL-2017-0003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45529508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Penumbral freeze: travel distance and delays provide an opportunity to study prerecanalization therapy neuroprotection","authors":"D. Blacker","doi":"10.2217/FNL-2017-0025","DOIUrl":"https://doi.org/10.2217/FNL-2017-0025","url":null,"abstract":"","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"12 1","pages":"185-188"},"PeriodicalIF":1.3,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/FNL-2017-0025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42669288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Fragile X–tremor/ataxia syndrome: five areas of new development","authors":"Ajal Dave, J. Hawley","doi":"10.2217/FNL-2017-0019","DOIUrl":"https://doi.org/10.2217/FNL-2017-0019","url":null,"abstract":"","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"12 1","pages":"249-260"},"PeriodicalIF":1.3,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/FNL-2017-0019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48933807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号